145 related articles for article (PubMed ID: 11524489)
21. Primary central nervous system lymphomas in immunocompetent patients.
Guinto G; Félix I; Aréchiga N; Arteaga V; Kovacs K
Histol Histopathol; 2004 Jul; 19(3):963-72. PubMed ID: 15168358
[TBL] [Abstract][Full Text] [Related]
22. Primary central nervous system lymphomas (PCNSL): MRI response criteria revised.
Schlegel U; Jürgens A; Pels H
Neurology; 2006 Apr; 66(8):1287; author reply 1287. PubMed ID: 16636266
[No Abstract] [Full Text] [Related]
23. Primary central nervous system lymphoma with testicular relapse.
Harney J; Pope A; Short SC
Clin Oncol (R Coll Radiol); 2004 May; 16(3):193-5. PubMed ID: 15191006
[TBL] [Abstract][Full Text] [Related]
24. High-dose methotrexate is beneficial in parenchymal brain masses of uncertain origin suspicious for primary CNS lymphoma.
Kiewe P; Loddenkemper C; Anagnostopoulos I; Reinwald M; Thiel E; Korfel A
Neuro Oncol; 2007 Apr; 9(2):96-102. PubMed ID: 17301290
[TBL] [Abstract][Full Text] [Related]
25. [Liposomal cytarabine in prophylaxis of the central nervous system involvement in rare aggresive lymphomas].
Kumiega B; Jurczak W; Fornagiel S; Dzietczenia J; Skotnicki AB
Przegl Lek; 2013; 70(4):187-90. PubMed ID: 23991555
[TBL] [Abstract][Full Text] [Related]
26. Flows and flaws in primary central nervous system lymphoma.
Ferreri AJ; Illerhaus G; Zucca E; Cavalli F;
Nat Rev Clin Oncol; 2010 Aug; 7(8):doi:10.1038/nrclinonc.2010.9-c1; author reply doi:10:1038/nrclinonc.2010.9-c2. PubMed ID: 20700952
[No Abstract] [Full Text] [Related]
27. Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemma.
Kim SJ; Oh SY; Kim JS; Kim H; Lee GW; Won JH; Shin HJ; Yang DH; Choi CW; Park J; Kim WS; Suh C
Ann Hematol; 2011 May; 90(5):539-46. PubMed ID: 20960190
[TBL] [Abstract][Full Text] [Related]
28. Surgical removal of primary central nervous system lymphomas (PCNSL) presenting as space occupying lesions: a series of 33 cases.
Bellinzona M; Roser F; Ostertag H; Gaab RM; Saini M
Eur J Surg Oncol; 2005 Feb; 31(1):100-5. PubMed ID: 15642434
[TBL] [Abstract][Full Text] [Related]
29. Post-treatment T1 shortening in primary CNS lymphoma.
Karimi S; Hatzoglou V; Punia V; Partovi S; Abrey LE; Deangelis LM
J Neurooncol; 2013 Jan; 111(1):25-31. PubMed ID: 23073601
[TBL] [Abstract][Full Text] [Related]
30. Primary central nervous system lymphoma.
Mohile NA; Abrey LE
Semin Radiat Oncol; 2007 Jul; 17(3):223-9. PubMed ID: 17591569
[TBL] [Abstract][Full Text] [Related]
31. High-dose methotrexate and primary central nervous system lymphoma.
Fahey JB; DiMaggio C
J Neurosci Nurs; 2007 Apr; 39(2):83-8. PubMed ID: 17477222
[TBL] [Abstract][Full Text] [Related]
32. Primary central nervous system lymphomas: salvage treatment after failure to high-dose methotrexate.
Reni M; Mazza E; Foppoli M; Ferreri AJ
Cancer Lett; 2007 Dec; 258(2):165-70. PubMed ID: 17993246
[TBL] [Abstract][Full Text] [Related]
33. Treatment approaches for primary CNS lymphomas.
Carrabba MG; Reni M; Foppoli M; Chiara A; Franzin A; Politi LS; Villa E; Ciceri F; Ferreri AJ
Expert Opin Pharmacother; 2010 Jun; 11(8):1263-76. PubMed ID: 20429667
[TBL] [Abstract][Full Text] [Related]
34. Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial.
Roth P; Martus P; Kiewe P; Möhle R; Klasen H; Rauch M; Röth A; Kaun S; Thiel E; Korfel A; Weller M
Neurology; 2012 Aug; 79(9):890-6. PubMed ID: 22895585
[TBL] [Abstract][Full Text] [Related]
35. Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis.
Sancho JM; Ribera JM; Oriol A; Hernandez-Rivas JM; Rivas C; Bethencourt C; Parody R; Deben G; Bello JL; Feliu E;
Cancer; 2006 Jun; 106(12):2540-6. PubMed ID: 16700036
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of polyglutamylation in primary central nervous system lymphoma.
Shinojima N; Fujimoto K; Makino K; Todaka K; Yamada K; Mikami Y; Oda K; Nakamura K; Jono H; Kuratsu JI; Nakamura H; Yano S; Mukasa A
Acta Neuropathol Commun; 2018 Feb; 6(1):15. PubMed ID: 29475458
[TBL] [Abstract][Full Text] [Related]
37. [Management of primary central nervous system lymphoma].
Gonzalez-Aguilar A; Houillier C; Soussain C; Hoang-Xuan K
Rev Neurol (Paris); 2011 Oct; 167(10):721-8. PubMed ID: 21906768
[TBL] [Abstract][Full Text] [Related]
38. Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma.
Green MR; Chowdhary S; Lombardi KM; Chalmers LM; Chamberlain M
Expert Rev Neurother; 2006 May; 6(5):635-52. PubMed ID: 16734512
[TBL] [Abstract][Full Text] [Related]
39. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
[TBL] [Abstract][Full Text] [Related]
40. Liposomal cytarabine in the prophylaxis and treatment of CNS lymphoma: toxicity analysis in a retrospective case series study conducted at Polish Lymphoma Research Group Centers.
Jurczak W; Kroll-Balcerzak R; Giebel S; Machaczka M; Giza A; Ogórka T; Fornagiel S; Rybka J; Wróbel T; Kumiega B; Skotnicki AB; Komarnicki M
Med Oncol; 2015 Apr; 32(4):90. PubMed ID: 25716885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
